HK1209323A1 - Esketamine for the treatment of treatment-refractory or treatment- resistant depression - Google Patents

Esketamine for the treatment of treatment-refractory or treatment- resistant depression

Info

Publication number
HK1209323A1
HK1209323A1 HK15110013.5A HK15110013A HK1209323A1 HK 1209323 A1 HK1209323 A1 HK 1209323A1 HK 15110013 A HK15110013 A HK 15110013A HK 1209323 A1 HK1209323 A1 HK 1209323A1
Authority
HK
Hong Kong
Prior art keywords
treatment
esketamine
refractory
resistant depression
depression
Prior art date
Application number
HK15110013.5A
Other languages
English (en)
Chinese (zh)
Inventor
Jaskaran Singh
Lodewijk Ivo Caers
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1209323A1 publication Critical patent/HK1209323A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15110013.5A 2012-03-12 2015-10-14 Esketamine for the treatment of treatment-refractory or treatment- resistant depression HK1209323A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261609641P 2012-03-12 2012-03-12
US201261610058P 2012-03-13 2012-03-13
PCT/US2013/030476 WO2013138322A1 (en) 2012-03-12 2013-03-12 Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Publications (1)

Publication Number Publication Date
HK1209323A1 true HK1209323A1 (en) 2016-04-01

Family

ID=47913632

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110013.5A HK1209323A1 (en) 2012-03-12 2015-10-14 Esketamine for the treatment of treatment-refractory or treatment- resistant depression

Country Status (14)

Country Link
US (2) US20130236573A1 (xx)
KR (1) KR20140136982A (xx)
CN (1) CN104519878A (xx)
CL (1) CL2014002406A1 (xx)
CO (1) CO7071129A2 (xx)
CR (1) CR20140410A (xx)
GT (1) GT201400191A (xx)
HK (1) HK1209323A1 (xx)
MX (1) MX2014010939A (xx)
NI (1) NI201400104A (xx)
PE (1) PE20141906A1 (xx)
PH (1) PH12014501997A1 (xx)
SG (1) SG11201405530SA (xx)
WO (1) WO2013138322A1 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
CN105377371A (zh) 2013-04-12 2016-03-02 西奈山伊坎医学院 创伤后应激障碍的治疗方法
RS62516B1 (sr) 2013-09-13 2021-11-30 Univ Chiba Nat Univ Corp Primena r-ketamina i njegove soli kao farmaceutskih proizvoda
US9610259B2 (en) * 2014-01-14 2017-04-04 Children's Hospital Medical Center Compositions and methods for treating an autism spectrum disorder
MX2016014581A (es) * 2014-05-06 2018-02-16 Univ Northwestern Composiciones de compuestos que modulan nmdar.
MX2017001908A (es) * 2014-08-13 2017-08-08 Janssen Pharmaceutica Nv Metodo para el tratamiento de la depresion.
EP3725307A1 (en) * 2014-09-15 2020-10-21 Janssen Pharmaceutica NV Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
EP3229788A4 (en) 2014-12-08 2018-06-13 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2016109427A1 (en) * 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017003935A1 (en) 2015-06-27 2017-01-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2018079693A1 (ja) * 2016-10-27 2018-05-03 国立大学法人 千葉大学 （ｓ）－ノルケタミンおよびその塩の医薬品としての応用
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN107823195A (zh) * 2017-11-24 2018-03-23 无锡市精神卫生中心 R‑氯胺酮在抑郁症急性期治疗中的应用
CN112423789A (zh) 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
HUE058320T2 (hu) 2017-12-29 2022-07-28 Celon Pharma Sa Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
BR112020016500A2 (pt) 2018-02-15 2020-12-15 National University Corporation Chiba University Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
WO2020027344A1 (en) * 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
EP3628313A1 (en) 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
CA3113198A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020168337A1 (en) * 2019-02-17 2020-08-20 Magid Abraham Compositions and methods for treatment of depression and other disorders
EP3934632A4 (en) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. ESKETAMINE FOR THE TREATMENT OF DEPRESSION
WO2020239243A1 (en) 2019-05-31 2020-12-03 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
WO2020239244A1 (en) 2019-05-31 2020-12-03 Celon Pharma S.A. An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
WO2021038500A2 (en) * 2019-08-28 2021-03-04 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of patients with major depressive disorder, including suicidality
EP4028085A4 (en) * 2019-09-13 2023-10-04 Janssen Pharmaceuticals, Inc. INTRANASAL ADMINISTRATION OF ESKETAMINE
JP2023527343A (ja) * 2020-05-28 2023-06-28 ヤンセン ファーマシューティカ エヌ．ベー． うつ病の治療方法
WO2023162987A1 (ja) * 2022-02-22 2023-08-31 国立大学法人京都大学 うつ病および／またはうつ状態の治療および／または予防用医薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
JP2009538331A (ja) * 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain

Also Published As

Publication number Publication date
CO7071129A2 (es) 2014-09-30
PE20141906A1 (es) 2014-12-05
CR20140410A (es) 2014-11-17
KR20140136982A (ko) 2014-12-01
US20140093592A1 (en) 2014-04-03
SG11201405530SA (en) 2014-11-27
GT201400191A (es) 2017-07-03
WO2013138322A1 (en) 2013-09-19
CL2014002406A1 (es) 2015-01-09
CN104519878A (zh) 2015-04-15
MX2014010939A (es) 2014-11-13
PH12014501997A1 (en) 2014-11-24
NI201400104A (es) 2016-11-30
US20130236573A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
HK1209323A1 (en) Esketamine for the treatment of treatment-refractory or treatment- resistant depression
HK1211475A1 (en) Combination therapy
IL263661A (en) Combination therapy for the treatment of glioblastoma
GB201212513D0 (en) Therapeutic agents
GB201304031D0 (en) Medical applicator
EP2906208A4 (en) THERAPEUTIC TREATMENT
GB201217439D0 (en) Combination therapy
HK1211986A1 (en) Platelet targeted treatment
GB201217704D0 (en) Therapeutic agents
GB201207305D0 (en) Therapy
IL237776B (en) Medical applicator
HK1210426A1 (en) Combination therapy
GB201207907D0 (en) Treatment of depression
HUE036419T2 (hu) Légzõszervi depresszió kezelése
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
EP2908871A4 (en) ABSTRACT PROCESSING TECHNIQUES
AP2015008270A0 (en) Preparation for the treatment of tuberculosis
GB201211543D0 (en) Combination therapy
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment
GB201212604D0 (en) New treatment
GB201223021D0 (en) Therapeutic agents
GB201214985D0 (en) Modified therapeutic agents
GB201213712D0 (en) Modified therapeutic agents
GB201212512D0 (en) Therapeutic agents